David Rubenstein

David Rubenstein

Company: Dermavant Sciences

Job title: CSO


David Rubenstein, M.D., Ph.D. currently serves as Chief Scientific Officer for Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in medical dermatology. Dr. Rubenstein joined Dermavant in March 2018 from GlaxoSmithKline Dermatology where he had built an industry-leading dermatology drug development organization as Vice President, Discovery and Preclinical Development. Prior to GSK, Dr. Rubenstein held academic roles at the University of North Carolina at Chapel Hill, most recently serving as the Louis C. Skinner Jr. Distinguished Professor of Dermatology. He is a board-certified dermatologist who continues to maintain a clinical practice at the University of North Carolina-Chapel Hill where he trains dermatology residents and provides care for patients with complex medical dermatology needs.

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.